Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases

While de-escalation of bisphosphonates from 4 to 12-weekly dosing has been shown to be clinically non-inferior to standard dosing, there is evidence the de-escalation is associated with increased bone turnover biomarkers. Here we evaluated the effect of de-escalated dosing on a panel of biomarkers a...

Descripción completa

Detalles Bibliográficos
Autores principales: Addison, Christina L, Pond, Gregory R, Zhao, Huijun, Mazzarello, Sasha, Vandermeer, Lisa, Goldstein, Robyn, Amir, Eitan, Clemons, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4194305/
https://www.ncbi.nlm.nih.gov/pubmed/25332877
http://dx.doi.org/10.1186/2193-1801-3-577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4194305/
https://www.ncbi.nlm.nih.gov/pubmed/25332877
http://dx.doi.org/10.1186/2193-1801-3-577

Ejemplares similares